Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.
about
Astatine-211: production and availabilityTrends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.Astatine Radiopharmaceuticals: Prospects and ProblemsClinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6Novel modular transporters delivering anticancer drugs and foreign DNA to the nuclei of target cancer cellsReagents for astatination of biomolecules. 4. Comparison of maleimido-closo-decaborate(2-) and meta-[(211)At]astatobenzoate conjugates for labeling anti-CD45 antibodies with [(211)At]astatine.An overview of targeted alpha therapy.Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.Targeted radiotherapy of brain tumours.Molecular targeted α-particle therapy for oncologic applications.A kit method for the high level synthesis of [211At]MABG.Monoclonal antibodies for brain tumour treatment.Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.Targeted alpha-therapy: past, present, future?Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generatorsMetallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals.Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.Bisphosphonates as radionuclide carriers for imaging or systemic therapy.Continuing pursuit for ideal systemic anticancer radiotherapeutics.The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma.Shelf-life of ɛ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, precursors for 211At labeling of antibodies.In vitro and in vivo studies of adenovirus-mediated human norepinephrine transporter gene transduction to hepatocellular carcinoma.In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma.Enhanced tumour uptake of radiolabelled antibodies by hyperthermia: Part I: Timing of injection relative to hyperthermia.Irradiation of Mesenchymal Stromal Cells With Low and High Doses of Alpha Particles Induces Senescence and/or Apoptosis.Astatine-211 labeled anti-HER2 5F7 single domain antibody fragment conjugates: radiolabeling and preliminary evaluation.Iodine-131 metaiodobenzylguanidine therapy for neuroblastoma: reports so far and future perspective.High-Activity Radio-Iodine Labeling of Conventional and Stealth Liposomes
P2860
Q27015038-27C82C9B-C47D-4D64-8166-D3BABE6CA86AQ33311571-2BAE5054-8BA5-4AE1-8BF8-89D0CBBB0A04Q33640550-A3EA7E5E-29CA-4EFE-BC9F-FB8CF54B0DEFQ33705446-70372A2E-224B-4029-ABFB-908201E8983CQ33709592-F4FF23F7-1EB4-4E27-95D6-60848824B6E6Q33925339-AAF6467D-0C18-4C47-B534-D738DE69AAC9Q34238513-48A55031-E847-44D4-859C-56BBBB58610DQ35602239-80AF0D6E-5089-4179-ACEC-6CA94B70C9E4Q35745251-3F09A7BD-8332-429B-B561-54EA9678DCEAQ35814989-3B44F097-2EDB-42DB-9FBA-E840E77FD770Q35828025-C2BA3ADC-2E4E-4206-ADF9-08FAAFDDFC4AQ35873775-5C59B74A-1529-4BB9-8F35-4C8ECEA3F746Q36154918-4C1115A4-79B8-484B-94BC-050968DAD64FQ36691184-F0057F94-500D-47BB-9774-FD27A68F0090Q36871613-A1EAC139-B23E-4D71-B626-2134BC8C1BA8Q36944649-E73ECDB6-44A8-4073-8378-ECC3C710D897Q37026964-B3CDB3A7-2884-4C6E-A005-9CABB5539E09Q37085052-B0C89844-9C80-4A1A-99B8-E074179AA238Q37676716-053C4F6B-A75A-4FE0-93CF-95081C01B13FQ37924117-79335C21-6AC5-4972-B78C-BFFA70F76E67Q37946750-E013DFC7-AC46-40E7-B36B-532CF1CC09B7Q38215613-7923BA59-4425-463F-8D96-9A497D06DF91Q38920099-AE47AF94-9618-4D72-AC62-5F7ADEB17B79Q39632795-1E9D66E0-E214-41B7-86DA-8C8CA8D94453Q40396031-0F16206D-3D10-4139-8991-DB80729EC1A5Q40447418-07D0115C-0770-4969-84A4-80684A8A55A2Q48045979-8EBAFA91-59B0-4773-BD38-BED866427B3BQ50068024-28D3F595-F49E-4008-AAC8-2E5939333E3CQ51125396-2ED524D0-3516-4E98-847D-5D4572380587Q57760579-D25E08FE-7587-428A-B925-80E705BB416E
P2860
Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Astatine-211-labeled radiother ...... d alpha-particle radiotherapy.
@ast
Astatine-211-labeled radiother ...... d alpha-particle radiotherapy.
@en
type
label
Astatine-211-labeled radiother ...... d alpha-particle radiotherapy.
@ast
Astatine-211-labeled radiother ...... d alpha-particle radiotherapy.
@en
prefLabel
Astatine-211-labeled radiother ...... d alpha-particle radiotherapy.
@ast
Astatine-211-labeled radiother ...... d alpha-particle radiotherapy.
@en
P356
P1476
Astatine-211-labeled radiother ...... d alpha-particle radiotherapy.
@en
P2093
Vaidyanathan G
Zalutsky MR
P304
P356
10.2174/1381612003399275
P577
2000-09-01T00:00:00Z